SecBot SecBot

ATNM

Actinium Pharmaceuticals, Inc.
NYSE· Pharmaceutical Preparations· Inc. DE· CIK 0001388320 Biotech & Drug Discovery
$1.41 +0.01 (+0.71%)
Oct 27 4:00 PM ET · prev $1.40
Market cap
$50.3M
Micro cap
Median target
$4.00
+184% · range $3.00–5.00
Next earnings
Nov 12
in 16 days · EPS est. −$0.26
1 year
−7.8%
from $1.53 · Oct 27
30 days
+19.5%
from $1.18
52-week range
$0.7490–1.69
−17% from high · low Aug 5
Avg volume 20D
248.5K
Oct 20 spike 900.3K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
5
analyzed by SecBot
SecBot read MIXED 4 reports · 90 days
Balance 1 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 3/4 ·Next Earnings date, Nov 12, 2026
Strongest NEUTRAL Actinium Pharmaceuticals filed its definitive proxy statement for the 2026 Annual Meeting, seeking to…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 4 added (0 new), 4 trimmed or exited.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.240 → −$0.255 over 90 days. 0 up, 1 down in 30 days.

  • TrendUPTREND

    20% above its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
Qube Research & Technologies LtdDOUBLED57,812$56.7K
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM56,822$55.7K
Vontobel Holding Ltd.ADD50,000$49.0K
UBS Group AGTRIM6,758$6.6K
MORGAN STANLEYTRIM6,341$6.2K
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CODOUBLED1,657$1.6K
JONES FINANCIAL COMPANIES LLLPDOUBLED1,351$1.3K
FEDERATED HERMES, INC.NEAR_EXIT137$134.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Mar 2026
12-month targets · 4 analysts

Price is below the lowest target. Median implies +184%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Mar 31, 2026Stephens & Co.
REITERATE
REITERATEOverweight
Jun 24, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
May 12, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Apr 28, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Apr 1, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy
Mar 27, 2025HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Oct 14, 2026
David Matthew T
Chief Financial Officer
AWARD250,000 sh
Oct 14, 2026
David Matthew T
Chief Financial Officer
AWARD250,000 sh
Sep 2, 2026
Almenoff June Sherie
Director
AWARD18,000 sh
Sep 2, 2026
Almenoff June Sherie
Director
AWARD27,000 sh
Sep 2, 2026
Chell Jeffrey W.
Director
AWARD61,600 sh
Sep 2, 2026
SETH SANDESH
Chief Executive Officer
AWARD753,600 sh
Sep 2, 2026
Steinhart Richard I
Director
AWARD62,800 sh
Sep 2, 2026
SETH SANDESH
Chief Executive Officer
AWARD1,130,400 sh

Earnings setup

Estimates
Nov 12
reports in 16 days
−$0.26
EPS estimate, this quarter
−6%
estimate change, 90 days
0↑ 1↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.26-$0.27–-$0.24+0.0%$0.00
Next Q-$0.23-$0.32–-$0.14+0.0%$0.00
Current FY$0.14$0.12–$0.16+0.0%$35.0M
Next FY-$0.53-$0.72–-$0.33+0.0%$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 Other
Actinium Pharmaceuticals Announces Inducement Grants to New Employees
NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actin
Oct 16, 2026 SEC
Actinium Pharmaceuticals filed its definitive proxy statement for the 2026 Annual Meeting, seeking to re-elect…
DEF 14A — Impact 3/10
Oct 15, 2026 SEC
Actinium Pharmaceuticals appointed Matt David, M.D. as CFO, effective October 14, 2026. Dr. David brings extensive…
8-K — Impact 3/10
Oct 14, 2026 Insider
David Matthew T was granted 250,000 shares
Chief Financial Officer
Oct 14, 2026 Insider
David Matthew T was granted 250,000 shares
Chief Financial Officer
Sep 2, 2026 Insider
Almenoff June Sherie was granted 18,000 shares
Director
Aug 14, 2026 Press
No summary provided
Impact 5/10
Aug 14, 2026 SEC
Actinium Pharmaceuticals received NYSE Regulation acceptance of its compliance plan, granting a maximum extension…
8-K — Impact 6/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
ATNM Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 16, 2026
Press release
Actinium Pharmaceuticals Announces Inducement Grants to New Employees
NEW YORK, Oct. 16, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the…
Oct 15, 2026
Press release
Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer
NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the…
Sep 4, 2026
Press release
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NEW YORK, Sept. 4, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development…
Aug 14, 2026
M&A
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
NEW YORK, Aug. 14, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development…
Aug 6, 2026
Earnings date
ATNM Q2 2026 Earnings Scheduled — 2026-08-06

SecBot reports

5 filings · 1 press release · 0 bullish · 3 bearish · 2 neutral
All ATNM filing & press-release reports (6)